of our fellow investors; grab, hanna, and wild, and that's quite OK of course.................
Personally, I'm more bullish on this company than ever.
Good luck All................................
wild, I think you are greatly mistaken. It is my opinion that Pfizer has a lot to do to catch up with RXI..
Do not discount the talents of Dr. Cauwenbergh and his staff. good luck All.......................
excalliard intradermally administered. wild, any idea of the reasons whyexc001 undergoing additional Ph2? thanks...............................................good luck All
Point taken, there is weak market, but how then does one explain the frequency and regularity of the trading. Look at the daily chart for the past year, it looks like a heartbeat monitor. I am not convinced that MM's are not whipsawing in and out to grab a piece of the spread.....................after all, they call the bid/ask...........
I,m sure that is one method of many IMO. Notice the size of the spread between bid and ask, at times quite large. In essence they can fill high ask order with their own shares. Notice the regularity of the trading on the daily chart . Also notice the frequency. It is nearly the same every day and for months on end.
It is license to steal IMHO.
I do not think this pattern is from retail investors buying and selling.
If I did not feel this company is as promising as I do, I'd be out. No so sure I'll be buying many otc stocks in the future.
I have a strong feeling that management and some of their heavier investors are aware of this and are working on the nasdaq issue as we speak . .........................good luck All
stockwatcher, this touches upon your subject, it was posted previously;
Simple fact; the SEC granted market makers the the ability to trade the very stocks they make a market for.
RXI would know through RXI's transfer agent who sells and who bought those shares.
Herein lies the problem; there is nothing ( that I can think of ) that RXI or any other company can do to prevent this activity. In the first place it is legal. Secondly, RXI cannot divulge to anyone who it is that is buying or selling shares in the company, for obvious reasons. No more than any of us would like our stock trades made public.
You can thank the SEC, and our government for allowing this activity which in my opinion is borderline criminal, no, just plain criminal. Inept government at its finest.
Not long ago MM's were not allowed to do this. How and why they were given this authority is beyond me.
So, I believe this is partly the reason RXI did the spit to get us on nasd. All bases were supposedly covered to uplist until nasd discovered a certain financing RXI placed earlier in the year, then nasd nixed the uplist until the stock began trading over $4.00. This was told to me directly by the company.
So, company's progress is stellar IMO, all on target, news today further confirming both safety and efficacy for a drug into Ph2 trials with a $4-5 B market potential, a well seasoned management team second to none, funding through Ph2, and a promising pipeline upcoming. But the stock is dead in its tracks.
For the life of me, I cannot think of other reasons why, but I'd certainly like to hear your views as to why...
Possibly wild. A partnership outside North America . It was mentioned by CEO earlier this year. That would most likely trade pps up to nasdaq...............good luck All
bio, no offense, but friends and neighbors do no follow investigational biotech companies, a little more targeted by the investment community don't you think?...........
But I agree with you, this company remains well under the radar of even the biotech investors................GLTA
idx, you are " quite dissapointed in the latest data", you sound like a stock basher to me. throwing out a lot of percentages does not impress this board. And your language does not equate that of a so called " research scientist".
Coupled with the fact your fist post on YMB was yesterday. Fraud basher for sure...........
Where do these guys come from anyway?..............................good luck All
idx, the Ph1 data along with the cohort date will be the basis for Ph2 dosing and scheduling. This is not an exact science, and precisely the reason for these trials.
I put my money on the RXI management. I might suggest that you do a little research on them, and then pose your questions directly to the company if you feel they are duly qualified.
Your post with all the percentages of this and that appear to me to be unprofessional and unstudied. no offense....................good luck All
lotta, many thanks for the heads up. Take I got from presentation:
3 Ph2 trials to determine optimal dose and schedule to demonstrate efficacy and safety which were initiated this month.. timeline by 2014. These trials move quickly by nature of visibility and timeliness of skin healing.
Very little distribution of compound beyond site of administration, along with no evidence of signs of accumulation in blood after repeated administration,(good sign as per safety).
Interim Ph2 results will be a very important tell tale for rxi-109. good luck All